A novel prognostic model based on AFP, tumor burden score and Albumin-Bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi: 10.1002/hep.29086.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Jia Z, Zhang H, Li N. Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the milan criteria: a systematic review and meta-analysis of recent randomized controlled trials. J Gastroenterol Hepatol. 2021;36(7):1769–1777. doi: 10.1111/jgh.15440.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018.
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Moris D, Hyer JM, et al. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg. 2020;107(7):854–864. doi: 10.1002/bjs.11464.
   PubMed Web of Science ®Google Scholar
• Fang KC, Kao WY, Su CW, et al. The prognosis of single large hepatocellular carcinoma was distinct from barcelona clinic liver cancer stage a or B: the role of albumin-bilirubin grade. Liver Cancer. 2018;7(4):335–358. doi: 10.1159/000487407.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58(1):89–97. doi: 10.1016/j.jhep.2012.09.020.
   PubMed Web of Science ®Google Scholar
• Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–1493. doi: 10.1245/s10434-019-07227-9.
   PubMed Web of Science ®Google Scholar
• Lin WP, Xing KL, Fu JC, et al. Development and validation of a model including distinct vascular patterns to estimate survival in hepatocellular carcinoma. JAMA Netw Open. 2021;4(9):e2125055. doi: 10.1001/jamanetworkopen.2021.25055.
   PubMed Web of Science ®Google Scholar
• Aziz S, Sey M, Marotta P, et al. Recurrent hepatocellular carcinoma after liver transplantation: validation of a pathologic risk score on explanted livers to predict recurrence. Transplant Proc. 2021;53(6):1975–1979. doi: 10.1016/j.transproceed.2021.05.007.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Morioka D, Conci S, et al. The tumor burden score: a new “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132–141. doi: 10.1097/SLA.0000000000002064.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi: 10.1200/JCO.2014.57.9151.
   PubMed Web of Science ®Google Scholar
• Vitale A, Lai Q, Farinati F, et al. Utility of tumor burden score to stratify prognosis of patients with hepatocellular cancer: results of 4759 cases from ITA.LI.CA study group. J Gastrointest Surg. 2018;22(5):859–871. doi: 10.1007/s11605-018-3688-y.
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria. Ann Surg. 2020;272(4):574–581. doi: 10.1097/SLA.0000000000004346.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Toyoda H, et al. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol. 2019;34(6):1066–1073. doi: 10.1111/jgh.14564.
   PubMed Web of Science ®Google Scholar
• Peng Y, Wei Q, He Y, et al. ALBI versus child-pugh in predicting outcome of patients with HCC: a systematic review. Expert Rev Gastroenterol Hepatol. 2020;14(5):383–400. doi: 10.1080/17474124.2020.1748010.
   PubMed Web of Science ®Google Scholar
• A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the cancer of the liver italian program (CLIP) investigators. Hepatology. 1998;28:751–755.
   PubMed Web of Science ®Google Scholar
• Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol. 2003;38(3):207–215. doi: 10.1007/s005350300038.
   PubMed Web of Science ®Google Scholar
• Leung TW, Tang AM, Zee B, et al. Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the okuda staging system, and the cancer of the liver Italian program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760–1769. doi: 10.1002/cncr.10384.
   PubMed Web of Science ®Google Scholar
• Okuda K, Obata H, Nakajima Y, et al. Prognosis of primary hepatocellular carcinoma. Hepatology. 1984;4(1 Suppl):3S–6S. doi: 10.1002/hep.1840040703.
   PubMed Web of Science ®Google Scholar
• Zhang Y-J, Liang H-H, Chen M-S, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology. 2007;244(2):e223091–607. doi: 10.1148/radiol.2442060826.
   Web of Science ®Google Scholar
• Huang G, Lin M, Xie X, et al. Combined radiofrequency ablation and ethanol injection with a multipronged needle for the treatment of medium and large hepatocellular carcinoma. Eur Radiol. 2014;24(7):1565–1571. doi: 10.1007/s00330-014-3151-8.
   PubMed Web of Science ®Google Scholar
• Huang GL, Liu M, Zhang XE, et al. Multiple-electrode switching-based radiofrequency ablation vs. conventional radiofrequency ablation for single early-stage hepatocellular carcinoma ranging from 2 to 5 Cm. Front Oncol. 2020;10:1150. doi: 10.3389/fonc.2020.01150.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Margonis GA, Andreatos N, et al. The prognostic utility of the “tumor burden score” based on preoperative radiographic features of colorectal liver metastases. J Surg Oncol. 2017;116(4):515–523. doi: 10.1002/jso.24678.
   PubMed Web of Science ®Google Scholar
• Hosmer DW, Hosmer T, Le Cessie S, et al. A comparison of goodness-of-fit tests for the logistic regression model. Statist Med. 1997;16(9):965–980. doi: 10.1002/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O.
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi: 10.1111/liv.14223.
   PubMed Web of Science ®Google Scholar
• Ma WJ, Wang HY, Teng LS. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol. 2013;11(1):212. doi: 10.1186/1477-7819-11-212.
   PubMed Web of Science ®Google Scholar
• Trevisani F, Garuti F, Neri A. Alpha-fetoprotein for diagnosis, prognosis, and transplant selection. Semin Liver Dis. 2019;39(2):163–177. doi: 10.1055/s-0039-1677768.
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Hyer JM, Diaz A, et al. Synergistic impact of alpha-fetoprotein and tumor burden on long-term outcomes following curative-intent resection of hepatocellular carcinoma. Cancers. 2021;13(4):13. doi: 10.3390/cancers13040747.
   Web of Science ®Google Scholar
• Moris D, Shaw BI, McElroy L, et al. Using hepatocellular carcinoma tumor burden score to stratify prognosis after liver transplantation. Cancers. 2020;12(11):12. doi: 10.3390/cancers12113372.
   Web of Science ®Google Scholar
• Ho SY, Liu PH, Hsu CY, et al. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol. 2022;16(9):903–911. doi: 10.1080/17474124.2022.2117156.
   PubMed Web of Science ®Google Scholar
• Huo TI. ALBI grade as a new player in hepatocellular carcinoma. J Chin Med Assoc. 2019;82(1):1. doi: 10.1016/j.jcma.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Michitaka K, et al. Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer. 2019;8(5):312–325. doi: 10.1159/000494844.
   PubMed Web of Science ®Google Scholar